Identification of preclinical dementia according to ATN classification for stratified trial recruitment: A machine learning approach

Author:

Koychev IvanORCID,Marinov Evgeniy,Young Simon,Lazarova Sophia,Grigorova Denitsa,Palejev Dean

Abstract

Introduction The Amyloid/Tau/Neurodegeneration (ATN) framework was proposed to identify the preclinical biological state of Alzheimer’s disease (AD). We investigated whether ATN phenotype can be predicted using routinely collected research cohort data. Methods 927 EPAD LCS cohort participants free of dementia or Mild Cognitive Impairment were separated into 5 ATN categories. We used machine learning (ML) methods to identify a set of significant features separating each neurodegeneration-related group from controls (A-T-(N)-). Random Forest and linear-kernel SVM with stratified 5-fold cross validations were used to optimize model whose performance was then tested in the ADNI database. Results Our optimal results outperformed ATN cross-validated logistic regression models by between 2.2% and 8.3%. The optimal feature sets were not consistent across the 4 models with the AD pathologic change vs controls set differing the most from the rest. Because of that we have identified a subset of 10 features that yield results very close or identical to the optimal. Discussion Our study demonstrates the gains offered by ML in generating ATN risk prediction over logistic regression models among pre-dementia individuals.

Funder

Alzheimer's Disease Neuroimaging Initiative

DOD ADNI

National Institute on Aging

National Institute of Biomedical Imaging and Bioengineering

AbbVie

Alzheimer's Association

Alzheimer's Drug Discovery Foundation

Araclon Biotech

BioClinica, Inc.

Biogen

Bristol-Myers Squibb Company

CereSpir, Inc.

Cogstate

Eisai Inc.

Elan Pharmaceuticals, Inc.

Eli Lilly and Company

EuroImmun

F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.

Fujirebio

GE Healthcare

IXICO Ltd.

Janssen Alzheimer Immunotherapy Research & Development, LLC.

Johnson & Johnson Pharmaceutical Research & Development LLC.

Lumosity

Lundbeck

Merck & Co., Inc.

Meso Scale Diagnostics, LLC.

NeuroRx Research

Neurotrack Technologies

Novartis Pharmaceuticals Corporation

Pfizer Inc.

Piramal Imaging

Servier

Takeda Pharmaceutical Company

Transition Therapeutics

Canadian Institutes of Health Research

Foundation for the National Institutes of Health

Northern California Institute for Research and Education

Alzheimer's Therapeutic Research Institute at the University of Southern California

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3